New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
10:24 EDTMJN, OREXOptions with increasing implied volatility: OREX MJN SWY
News For OREX;MJN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
07:32 EDTMJNMead Johnson reiterates FY15 adjusted EPS view $3.90-$4.00, consensus $4.00
Subscribe for More Information
07:32 EDTMJNMead Johnson reaffirms FY15 non-GAAP guidance
Subscribe for More Information
07:32 EDTMJNMead Johnson reports Q1 adjusted EPS $1.09, consensus $1.05
Subscribe for More Information
April 22, 2015
15:50 EDTMJNNotable companies reporting before tomorrow's open
Subscribe for More Information
07:37 EDTOREXOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 21, 2015
14:02 EDTOREXParagraph IV patent challenges submitted to FDA for Orexigen's Contrave
An Abbreviated New Drug Application, or ANDA, has been received by the Office of Generic Drugs containing a "Paragraph IV" patent certification for Contrave, the weight loss drug whose patent is owned by Orexigen Therapeutics, according to an FDA notice. The date on which the first substantially complete generic drug application was submitted to the Agency for Contrave was March 12, according to the posting. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use